Global PCR Technologies Market Size, Share, Growth, Analysis, Trends & Forecast to 2020

Share Article has announced the addition of the “Global PCR Technologies Market - Trends & Forecast to 2020” report to their offering. This 250-page report on the global Polymerase Chain Reaction (PCR) market states that the global PCR market will demonstrate a CAGR of over 9% during 2014 to 2020 and reach a market size of US$14 billion by end of 2020. View Full Report at

Global PCR Market’s Growth Shaping Factors

Dynamics such as increasing investments in drug discovery technologies and diagnostics, rising demand for innovative technologies for accurate and rapid diagnosis of life-threatening diseases, patent expiry, advanced digital polymerase chain reaction, growing applications in the fields of life sciences research, and clinical diagnostics and molecular testing are driving the PCR market growth. However, the global PCR industry will be suppressed due to factors such as high cost of some of the commercial PCR’s, emergence of alternate technologies such as next generation sequencing, stringent government regulations, shortage of skilled labor, and lack of awareness. The global polymerase chain reaction market is segregated into five main segments on the basis of products, techniques, applications, end-users, and geography.

Download Detail Report With Complete TOC at

Evaluation of Global PCR Market by Segments    

The global PCR market according to products is segmented into software, services, instruments, reagents and consumables. Further segmentation of these segments is derived across the geographies. The report states that the reagents and consumables segment commanded the largest chunk of the market and will grow at a strong CAGR during the forecast period, whereas the services sector is expected to demonstrate a high growth rate as well. By techniques, the global polymerase chain reaction market is divided into assembly PCR, hot start PCR, multiplex PCR, reverse transcriptase PCR, digital PCR, standard PCR, and real time PCR/qPCR. According to the report, real time quantitative PCR held the largest share in 2013, while digital PCR is expected to register the highest compound annual growth rate of around 13%.

Explore All Biotechnology Market Research Reports at

Application-wise, the global PCR market is segmented into clinical diagnostics, industrial applications, and others. The global polymerase chain reaction market by end users is segregated into academia, hospitals and laboratories, pharma and biotech firms and CRO’s, and others. Geography-wise, the report segments the global Polymerase Chain Reaction (PCR) market into North America, Europe, Asia Pacific, and Rest of World (LATAM, MINA, and others). North America dominated the largest share of the global PCR market and will demonstrate a steady growth in the coming years, owning to factors such as favorable government funding and enhanced healthcare infrastructure. On the other hand, Asia-Pacific region will display the highest growth with a CAGR of over 13% during 2014-2020. This growth rate is attributed to the increasing healthcare awareness, improving economic conditions, and rise in disposable incomes.

The global PCR market report includes profiles of prominent market players such as Becton, Dickinson and Company (U.S.), Abbott Laboratories, Inc. (U.S.), Qiagen N.V. (Netherlands), Promega Corporation (U.S.), Sigma Aldrich (U.S.), Siemens Healthcare (Germany), Bio-Rad Laboratories, Inc. (U.S.), Roche Diagnostics (Switzerland), and Thermo Fisher Scientific, Inc. (U.S.) etc.

Related Reports

Global And China Monoclonal Antibody Industry Report, 2014-2019

View Full Report at

Global blockbuster monoclonal antibody agents are still concentrated in Roche (Genentech), Amgen, AbbVie (Abbott), Johnson & Johnson, Novartis, etc. In 2013, the top 10 best-selling monoclonal antibody agents (Humira, Remicade, Enbrel, Rituxa, Avastin, Herceptin, Lucents, Synagis, Prolia/Xgeva and Erbitux, in order) mostly came from these companies mentioned above. Global sales of these ten monoclonal antibody agents totaled about USD 58.1 billion in 2013, and are predicted to amount to USD 64.1 billion in 2014.

Download Detail Report With Completge TOC at

These companies construct mature monoclonal antibody R&D platform, have unparalleled technical advantages in a series of processes including the selection of target gene, genetic sequencing, construction of monoclonal antibody structure and industrialized production, and are well-capitalized (R&D costs of these companies accounted for 15%-20% of revenue during the same period.). It is expected that they will keep a leading position in global monoclonal antibody market over the next five to ten years.

Global And China DNA Sequencing Industry Research Report, 2014-2017

View Full Report With COmplete TOC at

The upstream sectors of DNA sequencing industry are extremely robust, with the global market dominated by the second-generation DNA sequencing enterprises including Illumina, Thermo Fisher Scientific (through Life Technologies), Roche and the third-generation sequencing enterprises such as Pacific Biosciences. A review of these giants’ development history shows that mergers and acquisitions are the main driving forces behind the great market power. In February 2014, Roche acquired Life Technologies for USD13.6 billion, making it the industry giant second only to Illumina.

Download Detail Report With Complete TOC at

In China, the upstream sectors of DNA sequencing industry are virtually monopolized by foreign giants. BGI is the leader in China’s DNA sequencing service, and its second-generation DNA sequencers top the global chart in number. However, two of its sequencers—HiSeq 2000 and Ion Proton were entirely from Illumina and Life Technologies. In March 2013, BGI acquired Complete Genomics, a sign that BGI formally ventured into the upstream sectors of DNA sequencing industry. In June 2014, BGI’s two products—BGISEQ-1000 and BGISEQ-100 became the first second-generation DNA sequencers registered in China.

Global And China Stem Cell Industry Report, 2014-2017

View Full Report at

The stem cell technology and product research-oriented midstream sector is in its infancy, mostly concentrated in few countries like Europe, America and South Korea. At present, most companies in the industry chain are basically in the red for years running due to huge R&D costs. Nevertheless, attracted by the tremendous market potential in the area of stem cell therapy and enjoying the great encouragement from government policies (e.g. capital subsidy) and the capital support of significant cooperative partners, very few companies have dropped out.

Download Detail Report With COmplete TOC at

In the meantime, traditional pharmaceutical giants like Novartis are setting about quickly accessing the field through mergers and acquisitions. On Aug. 19, 2014, Novartis reached an acquisition agreement with Gamida Cell (a corporate dedicated to stem cell technology R&D and its application in stem cell transplantation for leukemia patients), which specified that Novartis spend USD35 million in acquiring 15% equity in the latter and win the option to take over the remaining equity in two years with USD165 million; in Sep. 2013, Novartis also entered a cooperation with Regenerex to jointly develop the hematopoietic stem cell platform FCRx of the latter.

About ( ) is the most comprehensive collection of market research reports, supporting clients’ market intelligence needs with over 100,000 market research reports, company profiles, data books, and regional market profits in its repository. We also offer consulting support for custom market research needs.

Our document database is updated by the hour, which means that our customers always have access to fresh data spanning over 300 industries. From Fortune 500 companies to SMEs, has built a veritable reputation for fulfilling the most exacting market research needs.

Browse Blog at

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Michell Thoras

Sheela AK
Follow us on
Visit website